Jasper Therapeutics(US:JSPR) Newsfileยท2025-11-07 02:02Core Viewpoint - Rosen Law Firm is encouraging investors of Jasper Therapeutics, Inc. to secure legal counsel before the November 18, 2025 deadline for a securities class action lawsuit related to the company's alleged misleading statements and lack of proper manufacturing controls [1][5]. Group 1: Class Action Details - Investors who purchased Jasper Therapeutics securities between November 30, 2023, and July 3, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by November 18, 2025 [3]. - The lawsuit claims that Jasper Therapeutics made false and misleading statements regarding its manufacturing controls and the regulatory prospects of its products, particularly briquilimab [5]. Group 2: Legal Representation - Investors are advised to select qualified legal counsel with a proven track record in securities class actions, as many firms may lack the necessary experience and resources [4]. - Rosen Law Firm has a history of successful settlements in securities class actions, including a record settlement against a Chinese company and significant recoveries for investors [4]. Group 3: Case Background - The lawsuit alleges that Jasper Therapeutics failed to ensure that third-party manufacturers complied with current Good Manufacturing Practices (cGMP), which could negatively impact the clinical and commercial prospects of its products [5]. - The failure to disclose these issues allegedly led to inflated public statements regarding the company's business and financial outlook [5].